Applied Therapeutics (NASDAQ:APLT - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Applied Therapeutics to post earnings of ($0.17) per share and revenue of $0.42 million for the quarter.
Applied Therapeutics Stock Down 2.1%
Shares of NASDAQ:APLT traded down $0.01 during trading on Friday, hitting $0.44. The stock had a trading volume of 673,519 shares, compared to its average volume of 1,572,010. Applied Therapeutics has a 12 month low of $0.30 and a 12 month high of $10.62. The company has a market capitalization of $62.39 million, a PE ratio of -1.02 and a beta of 1.96. The firm's fifty day moving average is $0.39 and its 200 day moving average is $0.46.
Analysts Set New Price Targets
A number of research analysts recently weighed in on APLT shares. Wall Street Zen raised Applied Therapeutics to a "sell" rating in a research report on Saturday, July 26th. Royal Bank Of Canada reissued a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $6.10.
View Our Latest Research Report on Applied Therapeutics
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Applied Therapeutics stock. AQR Capital Management LLC bought a new position in Applied Therapeutics Inc. (NASDAQ:APLT - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 572,311 shares of the company's stock, valued at approximately $280,000. AQR Capital Management LLC owned about 0.40% of Applied Therapeutics at the end of the most recent reporting period. 98.31% of the stock is currently owned by institutional investors.
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
See Also

Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.